279 related articles for article (PubMed ID: 21454245)
1. Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease.
Hershon KS
Endocr Pract; 2011; 17(3):430-40. PubMed ID: 21454245
[TBL] [Abstract][Full Text] [Related]
2. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
Scheen AJ
Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
[TBL] [Abstract][Full Text] [Related]
3. [Angiotensin II receptor blockers: current status and future prospects].
Corvol P; Plouin PF
Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
[TBL] [Abstract][Full Text] [Related]
4. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Martin J; Krum H
Pharmacol Res; 2002 Sep; 46(3):203-12. PubMed ID: 12220962
[TBL] [Abstract][Full Text] [Related]
5. Role of renin-angiotensin system blockade in patients with diabetes mellitus.
Braga MF; Leiter LA
Am J Cardiol; 2009 Sep; 104(6):835-9. PubMed ID: 19733720
[TBL] [Abstract][Full Text] [Related]
6. [NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].
Scheen AJ
Rev Med Liege; 2010 Apr; 65(4):217-23. PubMed ID: 20499825
[TBL] [Abstract][Full Text] [Related]
7. The blockade of renin-angiotensin-aldosterone system in hemodialysis patients to control hypertension and prevent cardiovascular disease: optimal pharmacotherapy.
Morishita Y; Kusano E
Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):241-6. PubMed ID: 22023537
[TBL] [Abstract][Full Text] [Related]
8. Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan.
Locatelli F; Palmer BF; Kashihara N; Ecder T
Curr Med Res Opin; 2009 Dec; 25(12):2933-49. PubMed ID: 19835466
[TBL] [Abstract][Full Text] [Related]
9. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Pfeffer MA
Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
[TBL] [Abstract][Full Text] [Related]
10. [Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Coca A; Giner V
Rev Esp Cardiol; 1999; 52 Suppl 3():53-8. PubMed ID: 10614150
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Lambers Heerspink HJ
Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
Burrell LM; Johnston CI
Drugs Aging; 1997 Jun; 10(6):421-34. PubMed ID: 9205848
[TBL] [Abstract][Full Text] [Related]
13. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
Lambers Heerspink HJ; Perkovic V; de Zeeuw D
J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
[TBL] [Abstract][Full Text] [Related]
15. It is time to reconsider the cardiovascular protection afforded by RAAS blockade -- overview of RAAS systems.
Tsukamoto O; Kitakaze M
Cardiovasc Drugs Ther; 2013 Apr; 27(2):133-8. PubMed ID: 22147138
[TBL] [Abstract][Full Text] [Related]
16. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.
Yarows SA
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):19-33. PubMed ID: 20030022
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
18. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
Chrysant SG
Drugs Today (Barc); 2010 Mar; 46(3):151-62. PubMed ID: 20467589
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
